Our first commercial assay will detect and individually identify 14 high-risk human papillomavirus (HR-HPV) genotypes, providing a powerful diagnostic and surveillance tool for clinicians and public health officials alike.
In advance of commercialisation, we’re looking to collaborate with a small cohort of key partners to support our Q-POC™ clinical performance and utility testing programme.
We’re looking to engage with potential collaborators early, to be able to support you with business planning and/or grant applications.
If your healthcare organisation would like to collaborate with us, please email us directly at: moc.xdmutnauq@sseccaylrae
You can also sign up for our dedicated HR-HPV newsletter here.